Acceleron Pharma to Present at Upcoming Investor and Medical Conferences in June
29 Mayo 2014 - 6:00AM
Business Wire
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel protein therapeutics for cancer and rare
diseases, today announced that over the next three weeks, it will
provide corporate presentations at several investor conferences and
host a conference call and webcast to review data presented at the
European Hematology Association’s annual meeting.
Date / Time: Wednesday, June 4, 2014 at
8:30 AM (EDT) Event: Jefferies 2014 Global Healthcare Conference
Location: New York City, New York Date / Time: Tuesday, June
10, 2014 at 4:00 PM (PDT) Event: Goldman Sachs 35th Annual Global
Healthcare Conference Location: Rancho Palos Verdes, California
Date / Time: Monday, June 16, 2014 at 8:00 AM (EDT) Event:
European Hematology Association (EHA) Conference Call and Data
Review Dial-in Information: 877-312-5848 (U.S.); 253-237-1155
(international) Date / Time: Tuesday, June 17, 2014 at 8:15
AM (EDT) Event: Wells Fargo Securities 2014 Healthcare Conference
Location: Boston, Massachusetts
A live audio webcast of each of these presentations will be
available on the “Events and Presentations” page in the Investors
& Media section on the Company’s website
(http://investor.acceleronpharma.com/events.cfm).
A replay of each of the webcasts will also be available from
Acceleron’s website.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused
on the discovery, development and commercialization of novel
protein therapeutics for cancer and rare diseases. The company is a
leader in understanding the biology of the Transforming Growth
Factor-Beta (TGF-β) protein superfamily, a large and diverse group
of molecules that are key regulators in the growth and repair of
tissues throughout the human body, and in targeting these pathways
to develop important new medicines. Acceleron has built a highly
productive R&D platform that has generated innovative clinical
and preclinical protein therapeutic candidates with novel
mechanisms of action. These protein therapeutic candidates have the
potential to significantly improve clinical outcomes for patients
with cancer and rare diseases.
For more information, please visit www.acceleronpharma.com.
Acceleron Pharma Inc.Kevin F. McLaughlin, 617-649-9204Senior
Vice President and Chief Financial OfficerorMedia:Suda
Communications LLCMaureen L. Suda, 585-387-9248
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
Real-Time news about Acceleron Pharma Inc (NASDAQ): 0 recent articles
Más de Acceleron Pharma Inc. (MM) Artículos de Noticias